Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Jong Jin | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yoon, Eileen | - |
dc.contributor.author | Kim, Tae Hyung | - |
dc.contributor.author | Kim, Dong Jin | - |
dc.contributor.author | Kang, Hyun Seok | - |
dc.contributor.author | Jung, Eun Suk | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | An, Hyonggin | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Lee, Hong Sik | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Kim, Chang Duck | - |
dc.contributor.author | Ryu, Ho Sang | - |
dc.date.accessioned | 2021-12-31T15:41:50Z | - |
dc.date.available | 2021-12-31T15:41:50Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2012-04 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/133862 | - |
dc.description.abstract | Background: Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. Aims: To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related decompensated cirrhosis patients. Methods: HBV-related decompensated cirrhosis patients [ChildTurcotte- Pugh (CTP) score >= 7] treated with either lamivudine or entecavir were enrolled. Serum HBV DNA levels, CTP score and Model for End-stage Liver Disease (MELD) score were monitored every 3 months. Results: Eighty-six patients were enrolled; mean age was 54 +/- 11 years, and 63 (73.3%) patients were men; 41 (47.7%) and 45 (52.3%) patients were assigned to the lamivudine group and entecavir group respectively. Although suppression of serum HBV DNA level was more potent in the entecavir group, CTP or MELD scores during the course of treatment did not differ between the two groups. Similarly, 6-month survival rates did not differ between the two groups (95.1 vs 93.2%, P = 0.684). Baseline CTP score and MELD score at 3 months of treatment were significantly associated with 6-month mortality. The 6-and 12-month mortality rates for patients with baseline CTP score >= 11 and MELD score >= 17.5 after 3 months of treatment were 42.9 and 61.9% respectively. Conclusions: Although HBV DNA suppression was more potent in the entecavir group than the lamivudine group, early mortality rates did not differ between the two groups. The baseline CTP score and MELD score 3 months after initiating antiviral treatment were significant predictors of early mortality. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | AWAITING LIVER-TRANSPLANTATION | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | COMPENSATED CIRRHOSIS | - |
dc.subject | NATURAL-HISTORY | - |
dc.subject | EARLY MORTALITY | - |
dc.subject | SURVIVAL | - |
dc.subject | DETERMINANTS | - |
dc.subject | MONOTHERAPY | - |
dc.subject | INFECTION | - |
dc.subject | THERAPY | - |
dc.title | Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hyun, Jong Jin | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | An, Hyonggin | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Lee, Hong Sik | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.contributor.affiliatedAuthor | Kim, Chang Duck | - |
dc.identifier.doi | 10.1111/j.1478-3231.2011.02676.x | - |
dc.identifier.scopusid | 2-s2.0-84858295076 | - |
dc.identifier.wosid | 000301233800018 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.32, no.4, pp.656 - 664 | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.citation.title | LIVER INTERNATIONAL | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 656 | - |
dc.citation.endPage | 664 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | AWAITING LIVER-TRANSPLANTATION | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | COMPENSATED CIRRHOSIS | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | EARLY MORTALITY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | DETERMINANTS | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | cirrhosis | - |
dc.subject.keywordAuthor | decompensation | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | hepatitis B virus | - |
dc.subject.keywordAuthor | lamivudine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.